Market Overview:
The global cryoprecipitated antihemophilic factor (AHF) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of hemophilia and other bleeding disorders, rising demand for recombinant AHF products and technological advancements in the field of AHF therapy. Based on type, the global cryoprecipitated AHF market is segmented into recombinant, plasma derived and others. The recombinant segment is anticipated to witness highest growth during the forecast period owing to its advantages such as high purity and longer shelf life as compared to plasma derived products. Based on application, hypofibrinogenemia accounts for majority share in terms of revenue in 2017; however, von Willebrand disease is expected to grow at highest CAGR over the forecast period due to increasing incidence rates across all regions.
Product Definition:
Cryoprecipitated Antihemophilic Factor (cryo-AHF) is a blood product derived from human plasma. It is used to treat and prevent bleeding in people with hemophilia A, a genetic disorder that causes the body to lack enough of a protein needed to form blood clots. Cryo-AHF contains high levels of this protein and can help control or prevent bleeding episodes.
Recombinant:
Recombinant hemophilia A is a genetic disorder that affects the blood clotting mechanism. It’s major symptoms are due to low levels of coagulation factor in the body. The disease is caused by mutations in the coagulation factor IX (Hemophilia A) gene, which codes for a protein necessary for proper blood clotting.
Plasma Derived:
Plasma derived and it's usage in Cryoprecipitated Antihemophilic Factor market is expected to witness lucrative growth over the forecast period owing to increasing R&D activities, rising prevalence of bleeding disorders, and growing demand for blood-clotting factor concentrates. According to the National Hemophilia Foundation (NHF), approximately 30,000 new cases are diagnosed each year in U.S., with a prevalence rate of about 1 per 40,000 population.
Application Insights:
Based on application, the global cryoprecipitated antihemophilic factor market is segmented into hypofibrinoginamia, von Williebrand disease, dysfibrinogenamia, hemophilia A, and other diseases. Hemophilia A held the largest share in terms of revenue in 2017 owing to increasing prevalence of the disorder coupled with high treatment costs. According to data published by WHO in 2014, around 10 million men are affected by hemophilia worldwide. In addition to this factoring out that only about 50% of patients diagnosed with hemophilia actually require a blood transfusion as compared to 90% required during medieval times when bleeding was considered normal and acceptable behavior for a man; these factors contribute towards increased demand for cryoprecipitated antihemophilic factor products among patients suffering from hemaphiliaA.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of pharmaceutical and biopharmaceutical companies, advanced healthcare infrastructure, favorable reimbursement policies for medicines consumed by patients suffering from bleeding disorders are some factors responsible for its largest share.
Asia Pacific is expected to be the fastest-growing region during the forecast period owing to increasing prevalence of vWD and uremia in developing countries such as India and China. In addition, growing medical tourism industry due to low treatment cost is also anticipated to boost Cryoprecipitated Antihemophilic Factor (CPAHF) market growth over the forecast period.
The key players operating in this space are Pfizer Inc.; CSL Ltd; AbbVie Inc.; FzioMed S.r.l.; BioMarin Pharmaceuticals Ltd; Chugai Pharmaceutical Co.
Growth Factors:
- Increasing prevalence of hemophilia and other bleeding disorders
- Growing demand for prophylactic treatment of hemophilia
- Rising number of surgical procedures requiring antihemophilic factor therapy
- Technological advancements in the manufacturing of antihemophilic factor products
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Cryoprecipitated Antihemophilic Factor Market Research Report
By Type
Recombinant, Plasma Derived, Others
By Application
Hypofibrinoginamia, Von Williebrand Disease, Dysfibrinogenamia, Hemophilia A, Uremia, Others
By Companies
Grifols, Baxter International, CSL Behring, RxList, Haemostatix, Shire US, Bio Products Laboratory, Novo Nordisk, BDI Pharma, Octapharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
204
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Cryoprecipitated Antihemophilic Factor Market Report Segments:
The global Cryoprecipitated Antihemophilic Factor market is segmented on the basis of:
Types
Recombinant, Plasma Derived, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hypofibrinoginamia, Von Williebrand Disease, Dysfibrinogenamia, Hemophilia A, Uremia, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Grifols
- Baxter International
- CSL Behring
- RxList
- Haemostatix
- Shire US
- Bio Products Laboratory
- Novo Nordisk
- BDI Pharma
- Octapharma
Highlights of The Cryoprecipitated Antihemophilic Factor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Recombinant
- Plasma Derived
- Others
- By Application:
- Hypofibrinoginamia
- Von Williebrand Disease
- Dysfibrinogenamia
- Hemophilia A
- Uremia
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cryoprecipitated Antihemophilic Factor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cryoprecipitated antihemophilic factor (CAPH) is a recombinant humanized form of the blood clotting protein, hemophilia A. It is used to treat people with hemophilia A who do not have enough natural circulating levels of the protein. CAPH can help prevent bleeding episodes and protect patients from joint damage caused by uncontrolled bleeding.
Some of the major players in the cryoprecipitated antihemophilic factor market are Grifols, Baxter International, CSL Behring, RxList, Haemostatix, Shire US, Bio Products Laboratory, Novo Nordisk, BDI Pharma, Octapharma.
The cryoprecipitated antihemophilic factor market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cryoprecipitated Antihemophilic Factor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cryoprecipitated Antihemophilic Factor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cryoprecipitated Antihemophilic Factor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cryoprecipitated Antihemophilic Factor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cryoprecipitated Antihemophilic Factor Market Size & Forecast, 2018-2028
4.5.1 Cryoprecipitated Antihemophilic Factor Market Size and Y-o-Y Growth
4.5.2 Cryoprecipitated Antihemophilic Factor Market Absolute $ Opportunity
Chapter 5 Global Cryoprecipitated Antihemophilic Factor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cryoprecipitated Antihemophilic Factor Market Size Forecast by Type
5.2.1 Recombinant
5.2.2 Plasma Derived
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cryoprecipitated Antihemophilic Factor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cryoprecipitated Antihemophilic Factor Market Size Forecast by Applications
6.2.1 Hypofibrinoginamia
6.2.2 Von Williebrand Disease
6.2.3 Dysfibrinogenamia
6.2.4 Hemophilia A
6.2.5 Uremia
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cryoprecipitated Antihemophilic Factor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cryoprecipitated Antihemophilic Factor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cryoprecipitated Antihemophilic Factor Analysis and Forecast
9.1 Introduction
9.2 North America Cryoprecipitated Antihemophilic Factor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cryoprecipitated Antihemophilic Factor Market Size Forecast by Type
9.6.1 Recombinant
9.6.2 Plasma Derived
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cryoprecipitated Antihemophilic Factor Market Size Forecast by Applications
9.10.1 Hypofibrinoginamia
9.10.2 Von Williebrand Disease
9.10.3 Dysfibrinogenamia
9.10.4 Hemophilia A
9.10.5 Uremia
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cryoprecipitated Antihemophilic Factor Analysis and Forecast
10.1 Introduction
10.2 Europe Cryoprecipitated Antihemophilic Factor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cryoprecipitated Antihemophilic Factor Market Size Forecast by Type
10.6.1 Recombinant
10.6.2 Plasma Derived
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cryoprecipitated Antihemophilic Factor Market Size Forecast by Applications
10.10.1 Hypofibrinoginamia
10.10.2 Von Williebrand Disease
10.10.3 Dysfibrinogenamia
10.10.4 Hemophilia A
10.10.5 Uremia
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cryoprecipitated Antihemophilic Factor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cryoprecipitated Antihemophilic Factor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cryoprecipitated Antihemophilic Factor Market Size Forecast by Type
11.6.1 Recombinant
11.6.2 Plasma Derived
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cryoprecipitated Antihemophilic Factor Market Size Forecast by Applications
11.10.1 Hypofibrinoginamia
11.10.2 Von Williebrand Disease
11.10.3 Dysfibrinogenamia
11.10.4 Hemophilia A
11.10.5 Uremia
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cryoprecipitated Antihemophilic Factor Analysis and Forecast
12.1 Introduction
12.2 Latin America Cryoprecipitated Antihemophilic Factor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cryoprecipitated Antihemophilic Factor Market Size Forecast by Type
12.6.1 Recombinant
12.6.2 Plasma Derived
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cryoprecipitated Antihemophilic Factor Market Size Forecast by Applications
12.10.1 Hypofibrinoginamia
12.10.2 Von Williebrand Disease
12.10.3 Dysfibrinogenamia
12.10.4 Hemophilia A
12.10.5 Uremia
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cryoprecipitated Antihemophilic Factor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cryoprecipitated Antihemophilic Factor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cryoprecipitated Antihemophilic Factor Market Size Forecast by Type
13.6.1 Recombinant
13.6.2 Plasma Derived
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cryoprecipitated Antihemophilic Factor Market Size Forecast by Applications
13.10.1 Hypofibrinoginamia
13.10.2 Von Williebrand Disease
13.10.3 Dysfibrinogenamia
13.10.4 Hemophilia A
13.10.5 Uremia
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cryoprecipitated Antihemophilic Factor Market: Competitive Dashboard
14.2 Global Cryoprecipitated Antihemophilic Factor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Grifols
14.3.2 Baxter International
14.3.3 CSL Behring
14.3.4 RxList
14.3.5 Haemostatix
14.3.6 Shire US
14.3.7 Bio Products Laboratory
14.3.8 Novo Nordisk
14.3.9 BDI Pharma
14.3.10 Octapharma
